BridgeBio Pharma, Inc.
BBIO
$32.19
-$0.82-2.48%
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 115.30% | 26.01% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 115.30% | 26.01% | |||
| Cost of Revenue | 248.49% | 0.00% | |||
| Gross Profit | 77.98% | 35.92% | |||
| SG&A Expenses | 37.73% | 15.62% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 19.67% | 8.61% | |||
| Operating Income | -18.28% | -8.39% | |||
| Income Before Tax | -62.09% | -117.43% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -62.79% | -117.43% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 5.65% | 6.03% | |||
| Net Income | -63.57% | -120.59% | |||
| EBIT | -18.28% | -8.39% | |||
| EBITDA | -18.52% | -8.49% | |||
| EPS Basic | -62.76% | -119.51% | |||
| Normalized Basic EPS | -23.26% | -5.88% | |||
| EPS Diluted | -62.76% | -119.51% | |||
| Normalized Diluted EPS | -23.26% | -5.88% | |||
| Average Basic Shares Outstanding | 0.49% | 0.49% | |||
| Average Diluted Shares Outstanding | 0.49% | 0.49% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
